| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(6 months ago) | |
| US7754731 | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(4 years from now) | |
| US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7217713 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
| US7435734 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
|
US7217713 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 12 days ago) | |
|
US7435734 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 12 days ago) | |
|
US7169780 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(29 days ago) | |
|
US7754731 (Pediatric) | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(5 years from now) | |
| US9649311 | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Oct, 2030
(6 years from now) | |
|
US9649311 (Pediatric) | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Apr, 2031
(6 years from now) | |
| US10772888 | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Mar, 2032
(7 years from now) | |
Isentress Hd is owned by Msd Sub Merck.
Isentress Hd contains Raltegravir Potassium.
Isentress Hd has a total of 12 drug patents out of which 6 drug patents have expired.
Expired drug patents of Isentress Hd are:
- US7217713
- US7435734
- US7217713*PED
- US7435734*PED
- US7169780*PED
- US7169780
Isentress Hd was authorised for market use on 12 October, 2007.
Isentress Hd is available in tablet;oral dosage forms.
Isentress Hd can be used as integrase inhibition for the treatment of hiv infection, treatment of hiv-1 infection, treatment of hiv infection.
Drug patent challenges can be filed against Isentress Hd from 22 May, 2020.
The generics of Isentress Hd are possible to be released after 30 March, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | May 26, 2020 |
| New Dosing Schedule(D-167) | May 26, 2020 |
| New Patient Population(NPP) | Dec 21, 2014 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
| M(M-114) | Mar 28, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
NCE-1 date: 22 May, 2020
Market Authorisation Date: 12 October, 2007
Treatment: Treatment of hiv infection; Integrase inhibition for the treatment of hiv infection; Treatment of hiv-1 infection
Dosage: TABLET;ORAL
ISENTRESS HD family patents
